Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program
The Optimizing Pharmacodynamic Target Attainment using the MYSTIC Antibiogram (OPTAMA) Program has been used globally to estimate antimicrobial exposures for either targeted pathogens or disease states. Herein, we utilised this methodology to determine antimicrobial exposures of cefepime, ceftazidim...
Saved in:
Main Authors: | , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2018
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/28123 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.28123 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.281232018-09-13T14:02:46Z Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program Pornpan Koomanachai Jared L. Crandon Joseph L. Kuti David P. Nicolau Hartford Hospital Mahidol University Medicine The Optimizing Pharmacodynamic Target Attainment using the MYSTIC Antibiogram (OPTAMA) Program has been used globally to estimate antimicrobial exposures for either targeted pathogens or disease states. Herein, we utilised this methodology to determine antimicrobial exposures of cefepime, ceftazidime, ciprofloxacin, imipenem, meropenem and piperacillin/tazobactam against European-derived isolates of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa obtained in 2006 and compared these with results from 2002. All regimens, except ciprofloxacin, provided optimal pharmacodynamic exposures against E. coli, whereas more regional differences were noted with K. pneumoniae. For K. pneumoniae, the carbapenems provided the highest likelihood of optimal exposures. Ciprofloxacin exposures were also noted to be low for both P. aeruginosa and A. baumannii. Moreover, for these two organisms higher doses and/or prolonged infusion of the studied β-lactams was necessary to obtain the desired pharmacodynamic targets. These data reveal regional differences in the probability of pharmacodynamic optimisation as well as the potential utility of employing regimens utilising higher doses and/or prolonged infusion techniques when directing therapy against P. aeruginosa and A. baumannii. © 2008 Elsevier B.V. and the International Society of Chemotherapy. 2018-09-13T07:02:46Z 2018-09-13T07:02:46Z 2009-04-01 Article International Journal of Antimicrobial Agents. Vol.33, No.4 (2009), 348-353 10.1016/j.ijantimicag.2008.08.023 09248579 2-s2.0-61449207852 https://repository.li.mahidol.ac.th/handle/123456789/28123 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=61449207852&origin=inward |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Medicine |
spellingShingle |
Medicine Pornpan Koomanachai Jared L. Crandon Joseph L. Kuti David P. Nicolau Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program |
description |
The Optimizing Pharmacodynamic Target Attainment using the MYSTIC Antibiogram (OPTAMA) Program has been used globally to estimate antimicrobial exposures for either targeted pathogens or disease states. Herein, we utilised this methodology to determine antimicrobial exposures of cefepime, ceftazidime, ciprofloxacin, imipenem, meropenem and piperacillin/tazobactam against European-derived isolates of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa obtained in 2006 and compared these with results from 2002. All regimens, except ciprofloxacin, provided optimal pharmacodynamic exposures against E. coli, whereas more regional differences were noted with K. pneumoniae. For K. pneumoniae, the carbapenems provided the highest likelihood of optimal exposures. Ciprofloxacin exposures were also noted to be low for both P. aeruginosa and A. baumannii. Moreover, for these two organisms higher doses and/or prolonged infusion of the studied β-lactams was necessary to obtain the desired pharmacodynamic targets. These data reveal regional differences in the probability of pharmacodynamic optimisation as well as the potential utility of employing regimens utilising higher doses and/or prolonged infusion techniques when directing therapy against P. aeruginosa and A. baumannii. © 2008 Elsevier B.V. and the International Society of Chemotherapy. |
author2 |
Hartford Hospital |
author_facet |
Hartford Hospital Pornpan Koomanachai Jared L. Crandon Joseph L. Kuti David P. Nicolau |
format |
Article |
author |
Pornpan Koomanachai Jared L. Crandon Joseph L. Kuti David P. Nicolau |
author_sort |
Pornpan Koomanachai |
title |
Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program |
title_short |
Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program |
title_full |
Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program |
title_fullStr |
Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program |
title_full_unstemmed |
Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program |
title_sort |
comparative pharmacodynamics for intravenous antibiotics against gram-negative bacteria in europe between 2002 and 2006: a report from the optama program |
publishDate |
2018 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/28123 |
_version_ |
1763488038084673536 |